euro adhoc: Capital measures / Curasan AG acquires rights to REVOIS® implant system

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

15.12.2006

Ad hoc announcement pursuant to Section 15 WpHG

Kleinostheim, December 15, 2006 - curasan AG (ISIN: DE 000 549 453
8), a company listed in the Prime Standard, has concluded an
agreement with the licensor of the REVOIS® implant system it
distributes, whereby the right of pre- emption concerning the
purchase of all legal rights associated with the aforementioned
product shall be executed with immediate effect. This decision was
prompted by the favourable response shown by both national and
international experts within the field.

Part of the purchase consideration is to be settled in the form of
500,000 new no-par-value shares, which shall be authorised for
trading and are to be issued from Authorised Capital I (Genehmigtes
Kapital I). Furthermore, additional purchase price components have
been agreed; they are to be financed via the future revenues
generated from the distribution of REVOIS®. Both parties have agreed
not to disclose details of the overall purchase price, which is
dependent on the product's sales performance.

Thus, curasan AG holds all rights for the manufacture and global
marketing of the REVOIS® implant system, including the rights
associated with trademarks and patent filings. In taking this step,
the company has ensured that investments in market development will
have a sustained positive effective on future corporate performance.

About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an
exchange-listed company, is a leading innovator within the growth
market of bone and tissue regeneration. The company has developed a
comprehensive product range centred around its synthetic bone
regeneration material Cerasorb®, for use in soft and hard tissue.
With the REVOIS implant system, the company's sales is focusing more
prominently on the growth market of dental surgery/implantology. The
majority of new products emerging from the substantial development
pipeline are to be offered under licence within other medical fields.
For further information, please visit curasan's corporate website at:
www.curasan.de

-----------------------

Ad hoc announcement

[pic][pic]

end of announcement euro adhoc 15.12.2006 08:19:45
--------------------------------------------------------------------------------

ots Originaltext: Curasan AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Dr. Erwin Amashaufer, curasan AG, Tel. (0) 6027/46 86-465, email: ir@curasan.de
Andrea Weidner, curasan AG, Tel. (0) 6027/ 46 86-467, E-Mail: pr@curasan.de

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade